Entrada Therapeutics, Inc. (TRDA): Shareholders' Equity
$306.13M
As of 2025-12-31
$233.41M
As of 2026-06-30
+12.9%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $306.13M | -28.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $428.68M | +76.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $242.36M | +14.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $212.55M | -28.8% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $298.72M | n/m | 2023-03-06, Balance as of period end |
| 2020-12-31 | -$41.49M | n/a | 2022-03-15, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $306.13M | -28.6% |
| Celularity Inc (CELU) | 2025-12-31 | -$38.06M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | $301.30M | +15.8% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $26.43M | +51.0% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$108.50M | n/m |
| Verastem, Inc. (VSTM) | 2025-12-31 | $57.20M | n/m |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$37.28M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗